Rising on the world stage, dengue fever is spread by mosquitoes and apparently air travel too. Dengue persists to remain a close affair with India as it appears in hundreds of deaths each year in the country, mostly because there is no particular treatment or precautionary medicines for the disease spread by mosquitoes. The single way to control the spread of this epidemic is to control the mosquito menace and restrict some people getting infected by this virus through this disease. But we are expecting that other means of controlling deaths due to dengue might develop soon. One of the recommended preventive measures is vaccination. There wasn’t a vaccination in place to prevent dengue till date.
But a few media reports have suggested that the pharma giant Panacea Biotec, has acquired permission to do clinical experiments in India in 2018 to test for the vitality of the vaccination for dengue they are coming up with. The approval was allowed by Drug Controller General of India. The clinical trials are said to begin in 2018, and the vaccine will be available often by end 2019. The mosquito-borne infection affects the platelet counts erodes immunity and causes deaths. This is why a vaccination can be of great help to lessen the number of fatalities happening every year.
Panacea Biotec, in cooperation with the National Institutes of Health, US, has produced the advanced dengue vaccine which promises safety and continues by the rules of preclinical studies. It is said that the single dose shot vaccine has been found to incite a robust immune response versus all four types of viruses in all age groups.
While we are eagerly waiting for a vaccination to come to the fore, in 2014 a group of scientists and researchers had expressed specific concerns about the dengue vaccination. Scientists have warned that dengue vaccines could cause short-term but significant heads in the years later they are first practised. Jan Medlock, an assistant professor at Oregon State University announced that their study recommended that if they produced and widely used a vaccine for dengue fever, there might later be spikes in the frequency of the disease that were two to three times higher than its average level. The experts analyzed at the OSU College of Veterinary Medicine and Clemson University, both of which helped the studies. Investigators used mathematical modelling to examine the quirks of infectious disease transmission that may lead to this puzzle. According to the scientists, the beginning of a treatment program would slow the numbers of children getting the disease, for a while. But it is supposed that a dengue vaccine would not give total assurance against contamination.
It was a 2014 report says that we are holding our fingers crossed assuming that things will better now, and the latest experimental drug will be capable of tide off these deficiencies.
If successful, this will be a significant accomplishment in fighting the infection which has so far hit over 200 people in India this year only. A total of 245 people died of dengue in 2016 and 220 the earlier year. According to the reports if things go as planned for the media giant then apparently with the introduction of the treatment dengue deaths can be controlled by 2019.